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ABSTRACT 
The mechanisms that link environmental and intracellular stimuli to mitochondrial 
functions, including fission and fusion, ATP production, metabolite biogenesis and apoptosis, are 
not well understood. Here, we demonstrate that the nutrient-sensing mechanistic/mammalian 
target of rapamycin complex 1 (mTORC1) stimulates translation of mitochondrial fission process 
1 (MTFP1) protein to control mitochondrial fission and apoptosis. Expression of MTFP1 is 
coupled to pro-fission phosphorylation and mitochondrial recruitment of the fission GTPase, 
dynamin-related protein 1 (DRP1). Potent active-site mTOR inhibitors engender mitochondrial 
hyperfusion due to the diminished translation of MTFP1 mediated by the translation initiation 
factor 4E (eIF4E)-binding proteins (4E-BPs). Uncoupling MTFP1 levels from the mTORC1/4E-
BP pathway upon mTOR inhibition blocks the hyperfusion response and leads to apoptosis by 
converting mTOR inhibitor action from cytostatic to cytotoxic. These data provide direct evidence 
for the survival function of mitochondrial hyperfusion upon mTOR inhibition by employing 
MTFP1 as a critical effector of mTORC1 to govern cell fate decisions. 
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INTRODUCTION 
The mechanistic/mammalian target of rapamycin (mTOR) integrates extracellular signals 
and intracellular cues (e.g. growth factors, insulin, nutrients and oxygen) to stimulate anabolism 
(e.g. protein and lipid synthesis) and bolster cellular growth and proliferation while suppressing 
catabolic processes (e.g. autophagy) (Efeyan et al., 2015; Laplante and Sabatini, 2012; 
Shimobayashi and Hall, 2014). mTOR is the catalytic subunit of two functionally distinct 
complexes named mTOR Complex 1 (mTORC1) and 2 (mTORC2) (Hara et al., 2002; Kim et al., 
2002; Sarbassov et al., 2004). mTORC1 is activated by growth factors and insulin via the PI3K-
AKT-TSC1/2 pathway and by amino acids via RAG small GTPases (Laplante and Sabatini, 2012; 
Zoncu et al., 2011). mTORC1 stimulates mRNA translation and other anabolic processes (e.g., 
lipid and nucleotide syntheses), but suppresses autophagy (Shimobayashi and Hall, 2014). 
mTORC2 controls cytoskeleton organization and cell survival by activating AGC kinase family 
members, and is implicated in regulating glucose and lipid metabolism (Laplante and Sabatini, 
2012; Shimobayashi and Hall, 2014).  
mTORC1 functions are mediated by multiple downstream effectors. Prominent ones 
include: translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs), ribosomal S6 kinases 
(S6Ks) and UNC-51-like kinase 1 (ULK1) (Bhat et al., 2015). 4E-BPs are translation initiation 
repressors, which bind to the mRNA 5’cap-binding protein eIF4E and prevent the assembly of the 
eIF4F complex that facilitates ribosome recruitment to the mRNA during translation initiation 
(Pause et al., 1994; Sonenberg and Hinnebusch, 2009). Phosphorylation of 4E-BPs by mTORC1 
results in their dissociation from eIF4E, thus allowing assembly of the eIF4F complex consisting 
of eIF4E, the DEAD box helicase eIF4A and the scaffold protein eIF4G, to promote translation 
initiation (Gingras et al., 1999).  
mTORC1 activation promotes the recruitment of selected mRNAs, including those 
encoding nuclear-encoded mitochondrial proteins, to ribosomes (Gandin et al., 2016; Larsson et 
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al., 2012; Morita et al., 2013). Increased translation is documented for subunits of oxidative 
phosphorylation complex I, III and V, and mitochondrial ribosomal subunit proteins (Gandin et 
al., 2016; Larsson et al., 2012; Morita et al., 2013). Increased translation augments mitochondrial 
biogenesis, respiration and energy production to drive cell growth and proliferation (Gandin et al., 
2016; Morita et al., 2013). Strikingly, the selected mRNAs also encode a protein relevant to 
mitochondrial fission, mitochondrial fission process protein 1 (MTFP1), also called MTP18. 
(Larsson et al., 2012). 
MTFP1 is an integral protein of the mitochondrial inner membrane, whose loss results in 
a hyperfused mitochondrial reticulum, whereas its overexpression engenders fragmentation 
(Tondera et al., 2005; Tondera et al., 2004; Wai and Langer, 2016). MTFP1 activity in 
mitochondrial fission is mediated by the essential fission GTPase, dynamin-related protein 1 
(DRP1) (Tondera et al., 2005). Previous studies have established that mitochondria hyperfuse upon 
nutrient deprivation through the PKA-dependent phosphorylation of DRP1, which blocks DRP1 
recruitment to mitochondria (Gomes et al., 2011; Rambold et al., 2011). However, links to 
mTORC1 signaling were not examined, and the functional significance of hyperfusion under these 
conditions remains unknown. 
In this study, we demonstrate that mTORC1 stimulates mitochondrial fission via 4E-BP-
mediated translational regulation of the mitochondrial fission factor, MTFP1. Suppression of 
mTORC1 activity by pharmacological or genetic means causes mitochondrial hyperfusion, 
branching and circularization. This is a consequence of downregulation of MTFP1 levels via the 
mTORC1/4E-BP pathway, thereby eliciting changes in phosphorylation and localization of the 
mitochondrial fission factor DRP1. Notably, the disruption of this mechanism upon mTOR 
inhibition results in cell death. Our results unveil a previously unknown signaling pathway that 
links the sensing of physiological stimuli by mTORC1 with mitochondrial morphology and cell 
survival.  
6 
 
RESULTS 
Active-site mTOR inhibitor induces mitochondrial hyperelongation and branching 
mTORC1 stimulates mitochondrial functions including respiration, the TCA cycle and 
biogenesis (Cunningham et al., 2007; Morita et al., 2013; Schieke et al., 2006), and enhances 
translation of selected mRNAs encoding mitochondrial proteins (Gandin et al., 2016; Larsson et 
al., 2012; Morita et al., 2013). Mitochondrial functions are linked to mitochondrial dynamics of 
fission and fusion (Friedman and Nunnari, 2014; Wai and Langer, 2016). To investigate whether 
the nutrient-sensing mTORC1 pathway affects mitochondrial dynamics, we first examined 
mitochondrial morphology in cells treated with an active-site mTOR inhibitor (asTORi) (Figures 
1, 2, S1 and S2). Using Transmission Electron Microscopy (TEM), we observed that the asTORi 
Ink1341-treated mouse embryonic fibroblasts (MEFs) displayed exaggerated mitochondrial 
elongation, branching and circularization as compared to vehicle-treated cells (Figures 1A and 1B, 
quantification in 1C-H). Quantitative analysis revealed that over 20% of mitochondria were 
elongated in asTORi-treated cells (> 2 Pm in length, 4% in vehicle control) (Figures 1C and 1H). 
asTORi-treated cells also showed mitochondrial branching, with 9% of mitochondria identified as 
branched, which was very rarely observed in vehicle-treated cells (Figure 1D). Total mitochondrial 
number and area per cytoplasmic area were decreased (by 27%) by asTORi as compared to control 
(Figures 1E and 1F). As reported previously (Sini et al., 2010; Thoreen et al., 2009), asTORi 
stimulated autophagosome formation (Figures 1B and 1G). The effect of the allosteric inhibitor of 
mTORC1, rapamycin, on mitochondrial dynamics was also tested (Figures S1A-D). Rapamycin-
treated cells displayed significant mitochondrial elongation compared to vehicle-treated cells 
(Figures S1A-D). In contrast to asTORi, quantitative analysis revealed that the effect of the 
rapamycin on mitochondrial morphology is milder than asTORi. Indeed, only 6% of mitochondria 
were elongated (> 2 Pm in length) in rapamycin-treated cells as compared to asTORi-treated cells 
(20%) (Figures S1D compared to 1H). Furthermore, rapamycin treatment rarely induced 
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mitochondrial branching (Figure S1C), which was observed in asTORi-treated cells (Figure 1D). 
Rapamycin decreased mitochondrial number per cytoplasmic area and promoted autophagosome 
formation (Figure S1C).  
To analyze the 3-D architecture of elongated mitochondria, Focused Ion Beam-Scanning 
Electron Microscopy (FIB-SEM) of 30 consecutive serial sections was performed (Figures 1I-J, 
S2A-B, and Movies S1-2). asTORi-treated cells exhibited elongation beyond 10 Pm with many 
branch points that led to circularization of mitochondria, which were not seen in vehicle-treated 
cells (Figures 1I-J, S2A-B and Movies S1-2). Cristae architecture appeared intact with no 
significant alterations. Confocal microscopy further corroborated the fused and branched 
mitochondrial phenotype seen in asTORi-treated cells relative to vehicle control (Figures 2A and 
2B). Mitochondria were elongated in more than 60% of cells treated with asTORi (Figure 2B). 
The hyperfusion and branching of mitochondria upon selective inhibition of mTOR provide strong 
evidence that mitochondrial dynamics are regulated by the mTOR signaling pathway. 
 
asTORi alters DRP1 localization and phosphorylation, and protein levels of the mitochondrial 
fission factor, MTFP1 
Mitochondrial fission is initiated by recruitment of the key fission factor DRP1 to 
mitochondria (Friedman and Nunnari, 2014; Wai and Langer, 2016). Confocal microscopy 
demonstrated that asTORi reduced DRP1 foci along the mitochondrial tubules (Figure 2C). This 
result was confirmed by subcellular fractionation analysis of DRP1 protein (Figure 2D). We thus 
assessed the effect of asTORi on levels and modifications of mitochondrial fission/fusion factors. 
A time course analysis of the changes in mitochondrial fission/fusion proteins over a 24 hr period 
in the presence of asTORi showed a 7-fold increase in phosphorylation of DRP1 at Ser 637 (S637) 
as compared to control (Figure 2E, and quantification in Figure S2C). Phosphorylation of DRP1 
at S637 prevents its translocation to the mitochondria (Cereghetti et al., 2008; Chang and 
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Blackstone, 2007; Cribbs and Strack, 2007). Conversely, the pro-fission phosphorylation site of 
DRP1 at Ser 616 (S616) (Qi et al., 2011; Taguchi et al., 2007; Yu et al., 2011) was decreased in 
asTORi-treated cells (Figure 2E, and quantification in Figure S2C). While total DRP1 was slightly 
reduced in asTORi-treated cells, there was a significant reduction (60%) in the mitochondrial 
fission protein, MTFP1 (Figure 2E, and quantification in Figure S2C), whose mRNA translation 
was reported to be suppressed by asTORi in a genome-wide interrogation of the translatome 
(Larsson et al., 2012). In contrast, the levels of the mitochondrial fission factor (MFF) and the 
fusion GTPases, mitofusin 2 (MFN2) and optic atrophy 1 (OPA1) were not affected by asTORi 
(Figure 2E). As reported (Feldman et al., 2009; Thoreen et al., 2009; Yu et al., 2009), asTORi 
abolished the phosphorylation of 4E-BP1 and S6K1, and led to a reduction in LC3-I (cytoplasmic 
form) levels and an increase in LC3-II (membrane-bound lipidated form) (Figure 2E, and 
quantification in Figure S2C), confirming the induction of autophagy (Figure 1G). Compared to 
asTORi, including Ink1341 and Torin1, rapamycin exerted a lesser effect on DRP1 
phosphorylation at S616 and S637 and no effect on MTFP1 protein levels (Figure S1E). In 
agreement with previous reports (Feldman et al., 2009; Thoreen et al., 2009), rapamycin and 
asTORi inhibited the S6K1 phosphorylation to the same extent, but rapamycin only partially 
inhibited the 4E-BP1 phosphorylation (Figure S1E), indicating that the differential effects of 
rapamycin and asTORi on mitochondrial dynamics depends on 4E-BPs. Thus, asTORi affects 
DRP1 phosphorylation and reduces expression of MTFP1, without major alterations in levels of 
other mitochondrial fission/fusion factors. 
 
mTORC1, but not mTORC2, induces mitochondrial fragmentation 
 asTORi inhibits both mTORC1 and mTORC2 (Benjamin et al., 2011). To determine 
which mTOR complex controls mitochondrial fission, mitochondrial morphology was examined 
in MEFs lacking either raptor or rictor (Cybulski et al., 2012), which are subunits of mTORC1 and 
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mTORC2, respectively (Figures 3A-C and S3A-B). In raptor knockout (KO) MEFs, over 50% of 
cells exhibited mitochondrial elongation, whereas there was no change in mitochondrial 
morphology in rictor KO cells (Figures 3A-C and S3A-B). Reduced recruitment of DRP1 to 
mitochondria was also evident in raptor, but not rictor KO cells (Figures 3A-B). DRP1 
phosphorylation at S616 was decreased, and the inhibitory S637 phosphorylation increased by 
raptor deletion (Figure 3D, quantification in Figure S3C). The total amount of DRP1 was mildly 
reduced (21%) in raptor-deleted cells (Figure 3D, quantification in Figure S3C), as compared to 
asTORi treatment (Figure 2D). MTFP1 protein level was decreased by 40% upon raptor deletion 
(Figure 3D, quantification in Figure S3C). Raptor KO had no effect on protein levels of the 
mitochondrial fusion factor, OPA1 (Figure 3D). In sharp contrast to raptor, rictor deletion had no 
effect on the levels of mitochondrial fission factors, DRP1 and MTFP1 (Figure 3E, quantification 
in Figure S3C). S6K1 and 4E-BP1 phosphorylation was decreased in raptor, but not in rictor KO 
MEFs (Figures 3D-E). These data demonstrate that mTORC1, but not mTORC2, mediates the 
effect of asTORi on expression of mitochondrial fission factors and mitochondrial morphology. 
To corroborate the role of mTORC1 in mitochondrial fission, we employed TSC2 KO 
cells in which mTORC1 is constitutively active (Zhang et al., 2003). As reported (Jaeschke et al., 
2002; Zhang et al., 2003), TSC2 KO MEFs exhibited elevated phosphorylation of 4E-BP1 and 
S6K1 as compared to wild-type (WT) MEFs (Figure 4A). An increase in DRP1 phosphorylation 
on S616, a decrease on S637 and an increase in DRP1 and MTFP1 protein levels were observed 
in TSC2 KO relative to WT (Figure 4A, quantification in Figure S3D). Consistently, loss of TSC2 
promoted mitochondrial fission (Figures 4B and 4C). Mitochondria were fragmented in 38% of 
TSC2 KO cells (Figure 4C). These results further support the conclusion that mTORC1 drives 
mitochondrial fragmentation by controlling the mitochondrial fission factors including DRP1 and 
MTFP1. 
 
10 
 
4E-BPs are required for the mTORC1-dependent regulation of mitochondrial structure and the 
asTORi-induced translational arrest of Mtfp1 mRNA 
The above described data documented the effects of the mTORC1 pathway on two 
branches of the mitochondrial division machinery; first through the regulation of DRP1 
phosphorylations, and second through the reduction in MTFP1. We have previously identified 
mRNAs whose translation is selectively suppressed by mTOR inhibition using genome-wide 
polysome profiling (Larsson et al., 2012). Among the suppressed mRNAs was the fission factor, 
MTFP1. 4E-BPs are major mediators of mTORC1-dependent regulation of mRNA translation 
(Sonenberg and Hinnebusch, 2009). To investigate the contribution of selective regulation of 
mRNA translation to mitochondrial hyperfusion, we examined the effects of asTORi in MEFs 
lacking 4E-BP1 and 4E-BP2 (Petroulakis et al., 2009). These cells are devoid of the three 4E-BPs, 
as MEFs do not express 4E-BP3 (Dowling et al., 2010). In striking contrast to the results obtained 
in WT MEFs (Figure 1), the effect of asTORi on mitochondrial branching was abolished and 
hyperfusion was significantly reduced in 4E-BP1 and 4E-BP2 double knockout (4E-BP DKO) 
MEFs, as determined by TEM (Figures 5A-F and S4A-D). 7% of mitochondria were elongated (> 
2 Pm in length) in 4E-BP DKO cells treated with asTORi (as compared to 20% in asTORi-treated 
WT cells), which was comparable to what was observed in vehicle-treated cells (Figures 5C and 
S4D). In contrast to WT MEFs, branched mitochondria were rarely observed in 4E-BP DKO cells 
treated with asTORi (9% vs 1% for 4E-BP WT and DKO, respectively) (Figure 5D), whereas 
autophagosome formation was induced by asTORi in both cells (Figure 5F). Confocal microscopy 
confirmed that deletion of 4E-BPs reversed the effect of asTORi on mitochondrial elongation 
(Figure 5G). Furthermore, DRP1 association with mitochondria was unaltered by asTORi in 4E-
BP DKO MEFs (Figure 5H), in sharp contrast to WT MEFs (Figure 2C). Hence, the effect of 
mTORC1 on mitochondrial morphology is mediated by 4E-BPs. 
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We have verified the translational suppression of Mtfp1 mRNA by asTORi PP242 (38% 
decrease) (Figure S4E), whereas no significant change (FDR > 0.05) in Drp1 mRNA translation 
was observed (Larsson et al., 2012). This result was also confirmed using polysome profiling in 
Ink1341-treated cells (Figures 6A and 6B). Ink1341 inhibited global mRNA translation in WT 
MEFs, as illustrated by a decrease in heavy polysome fractions with a concomitant increase in the 
80S peak (Figure 6A). Consistent with a reduction in MTFP1 protein in asTORi-treated cells 
(Figure 2E), asTORi inhibited the translation of Mtfp1 mRNA, as illustrated by a shift of this 
mRNA toward lighter fractions (Figure 6B). As reported previously (Dowling et al., 2010), cyclin 
D3 mRNA was shifted to light polysomes by asTORi, while E-actin mRNA was not (Figure 6B). 
Mtfp1 mRNA levels were not altered by asTORi treatment (Figure S4F). These data further 
demonstrate that mTORC1 regulates MTFP1 expression at the level of translation. 
In 4E-BP DKO MEFs, asTORi impaired global polysome formation to a lower extent as 
compared to their WT counterparts, as illustrated by a smaller increase in the 80S monosomes 
peak and a decrease in polysomes (compare Figures 6C to 6A). asTORi failed to induce a shift of 
Mtfp1 and Cyclin D3 mRNAs toward lighter fractions in 4E-BP DKO cells (Figure 6D), indicating 
that 4E-BPs repress translation of these mRNAs. Accordingly, the suppression of MTFP1 protein 
expression by asTORi observed in WT cells was attenuated in 4E-BP DKO MEFs (Figure 6E, 
quantification in Figure S4G). The deletion of 4E-BPs reversed the effects of asTORi on DRP1 
S616 and S637 phosphorylation (Figure 6E, quantification in Figure S4G). 
Translational activity of eIF4E is regulated through interaction with 4E-BPs as well as 
eIF4E phosphorylation induced by the MAPK/MNK signaling pathway (Bhat et al., 2015; 
Topisirovic et al., 2004). To further study the role of the 4E-BP/eIF4E axis in mitochondrial 
dynamics, we treated WT MEFs with phorbol 12-myrustate 13-acetate (PMA) that activates the 
MAPK pathway and enhances eIF4E phosphorylation (Goto et al., 2009) (Figures S5A-C). PMA-
treatment induced an increase in DRP1 S616 phosphorylation and DRP1 and MTFP1 protein levels 
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with a concomitant decrease in S637 phosphorylation (Figure S5A), and correlated with a strong 
mitochondrial fragmentation phenotype (70% of cells with fragmented mitochondria in PMA-
treatment compared to 20% in controls) (Figures S5B and S5C).  
To show that the role of the mTORC1/4E-BP axis in mitochondrial dynamics is not 
restricted to MEFs, we examined the effect of asTORi treatment on A375 human malignant 
melanoma 4E-BP1/2 WT and DKO cells, engineered by the CRISPR technology (Figures S5D-F). 
Compared to 4E-BP DKO A375 cells, WT A375 cells treated with asTORi exhibited a significant 
increase of mitochondrial hyperfusion correlated to a decrease in levels of MTFP1 protein and 
DRP1(S616) phosphorylation (Figures S5D-F), phenocopying asTORi-treated WT MEFs (Figures 
2A, 2B and 2E). In conclusion, 4E-BPs function as mediators of mTORC1 on downstream 
mitochondrial fission through the translational control of the mRNA encoding the mitochondrial 
fission protein, MTFP1. 
  
MTFP1 is the major mediator of the mTORC1/4E-BP-directed control of mitochondrial 
morphology 
The mitochondrial elongation phenotype observed as a result of asTORi treatment is 
characterized by an 4E-BP-dependent decrease of the MTFP1 protein level and an alteration of the 
S616 and S637 DRP1 phosphorylation. To elucidate the relationship and chronology of these two 
phenomena, rescue experiments were performed in MEFs treated with asTORi that expressed 
phospho-DRP1 mutants fused with GFP (Figure S6A-D). Cells transiently expressing GFP-DRP1-
WT, GFP-DRP1-S616D (phospho-mimetic mutant), GFP-DRP1-S637A (non-phosphorylatable 
mutant) and double GFP-DRP1-S616D/S637A were treated with asTORi or vehicle for 24 hr 
(Figure S6B), and mitochondrial morphology was analyzed by confocal microscopy (Figures S6C 
and S6D). All GFP-DRP1 mutants were well expressed (Figures S6A and S6B) with GFP1-DRP1-
637A and GFP-DRP1-S616D/S637A localized to mitochondria and leading to mitochondrial 
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fragmentation (Figure S6C and S6D). However, the DRP1 mutants only partially rescued (20%) 
the mitochondrial hyperfusion induced by asTORi (control cells treated with asTORi presented 
65% of elongated mitochondria compared to 46%, 46%, 41% and 40% for GFP-DRP1-WT, GFP-
DRP1-S616D, GFP-DRP1-S637A and GFP-DRP1-S616D/S637A, respectively) (Figures 2A-B 
and S6C-D). 
We therefore wished to determine whether translational suppression of the fission factor, 
MTFP1, underlies the effect of the mTORC1/4E-BP axis on mitochondrial fission. We rescued 
the expression of MTFP1 using a construct lacking the mRNA 5’UTR that is translationally 
sensitive to mTOR inhibition (Thoreen et al., 2012), to render its translation 4E-BP-independent 
(Figure 7A). Accordingly, asTORi reduced MTFP1 protein levels in control, but not in cells 
expressing the mutant MTFP1, while 4E-BP1 phosphorylation was suppressed equally in both 
cells (Figure 7A). MTFP1 expression stabilized the pro-fission S616 phosphorylation of DRP1, 
and reduced S637 phosphorylation in the presence of asTORi (Figure 7A, quantification in Figure 
S7A). Consistent with a previous report (Tondera et al., 2005), expression of MTFP1 increased 
mitochondrial fragmentation (Figures 7B and 7C). Importantly, compared to DRP1-mutants, 
MTFP1 re-expression fully blocked the mitochondrial hyperfusion induced by asTORi (Figures 
7B and 7C). Similar rescue experiments were performed in raptor KO cells (Figures S7B-D), 
where overexpression of MTFP1 induced mitochondrial fragmentation (Figures S7C and S7D) 
and rescued both the mitochondrial elongation and the decrease in DRP1 S616 phosphorylation 
observed in raptor KO cells (Figures S7B-D). 
Finally, to confirm that the increased expression of MTFP1 was responsible for the 
fragmented mitochondrial phenotype in the mTORC1 signaling-activated cells (Figures 4 and 
S3D), knockdown of MTFP1 by siRNA was performed (Figure S7E-G). MTFP1 silencing 
significantly induced mitochondrial hyperfusion in both TSC2 WT and KO MEF cells (Figures 
S7F and S7G), accompanied by a decrease in the phosphorylation of DRP1 at S616 (Figure S7E). 
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These data demonstrate that the loss of MTFP1 is responsible for the drastic mitochondrial 
hyperfusion seen upon inhibition of the mTORC1/4E-BP signaling pathway. 
 
asTORi-induced loss of MTFP1 protects cells from death  
The observation that mTOR inhibition leads to mitochondrial hyperfusion could provide 
an explanation for the cytostatic action of mTOR inhibitors (Benjamin et al., 2011). It has 
previously been suggested that the induction of mitochondrial hyperfusion during starvation 
renders mitochondria refractive to autophagy and protects cells against apoptosis (Gomes et al., 
2011). We therefore employed the rescue of MTFP1 expression to examine the functional 
contribution of mitochondrial hyperfusion to asTORi action. asTORi Ink1341 and Ink128 
dramatically reduced proliferation of cells expressing Mtfp1 mRNA, which is refractory to 4E-BP-
dependent translational regulation, as compared to control cells (Figures 7D and 7E). The re-
expression of 4E-BP-refractory MTFP1 induced poly (ADP-ribose) polymerase (PARP) cleavage 
(Figure S7H) and enhanced caspase-3/7 activity (Figure 7F), both hallmark phenomena of 
apoptosis, after 48 hr of treatment with asTORi. These data demonstrate that the impairment of 
mitochondrial hyperfusion caused by uncoupling of MTFP1 expression from the mTORC1/4E-BP 
pathway converts asTORi action from cytostatic to cytotoxic, which could be exploited to improve 
the anti-neoplastic efficacy of mTOR inhibitors in the clinic. 
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DISCUSSION 
 We demonstrate that asTORi treatment leads to dramatic mitochondrial branching and 
hyperfusion specifically mediated through the mTORC1/4E-BP/MTFP1 axis. Indeed, asTORi can 
target mTORC1 and mTORC2; however, the use of raptor and rictor KO MEFs clearly determine 
that mTORC1 is solely responsible for our phenotype (Figure 3). Moreover, the 4E-BPs deletion 
reverses mitochondrial hyperfusion and down-regulation of Mtfp1 mRNA translation induced by 
asTORi (Figures 5 and 6). The specificity of the mTORC1/4E-BP has been confirmed by the 
magnitude of the effects of asTORi and rapamycin treatments. Indeed, we show that asTORi leads 
to a more dramatic mitochondrial elongation than rapamycin (Figures 1, 2, S1 and S2). In both 
treatments, DRP1 phosphorylation states are altered to a lesser extent in rapamycin, and  
rapamycin does not decrease the MTFP1 protein level most probably due to the lack of 4E-BP1 
phosphorylation inhibition as reported previously (Feldman et al., 2009; Thoreen et al., 2009). 
Furthermore, the 4E-BP/eIF4E axis was reported to modulate translation of a series of mTORC1-
sensitive mRNAs encoding proliferation- and survival-promoting proteins (e.g., cyclins, BCL-2, 
MCL-1 and MYC) (Dowling et al., 2010; Gandin et al., 2016; Larsson et al., 2007; Larsson et al., 
2012), indicating that 4E-BPs contribute to cell survival upon mTOR inhibition via several target 
mRNAs. Our findings suggest that concomitant inhibition of the mTORC1 activity and 
mitochondrial fusion may be used to increase cytotoxicity and the anti-neoplastic efficacy of 
mTOR inhibitors in the clinic.  
 MTFP1 is a critical regulator of DRP1 phosphorylation downstream of the mTORC1 
signaling pathway. Accordingly, rescue of MTFP1 expression in asTORi-treated, raptor KO and 
TSC2 KO cells completely reverses both mitochondrial morphology and DRP1 phosphorylation 
states (Figures 7 and S7), whereas expression of phospho-DRP1 mutants partially rescues 
mitochondrial elongation (Figure S6). These results underscore the central role of MTFP1 in the 
control of mitochondrial dynamics upstream of DRP1 during mTOR inhibition; however, how 
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MTFP1, an inner mitochondrial membrane protein, controls DRP1 phosphorylation is an open 
question. The data imply a retrograde signaling pathway between MTFP1 and the kinases that 
phosphorylate DRP1 to regulate fission. MTFP1 is an integral inner membrane protein of 18 kDa 
with no known function (Tondera et al., 2005). Interestingly, it was recently established that at 
least one key signal for mitochondrial division is the local replication of mtDNA (Lewis et al., 
2016; Murley et al., 2013). mtDNA is packaged within nucleoids, and nucleoids with newly 
replicated DNA mark the sites of contact with the ER, leading to fission and successful segregation 
of the mitochondrial genomes (Murley et al., 2013). Whether MTFP1 participates in this signaling 
process is unclear. However, it is noteworthy that a major component of mtDNA nucleoids, 
transcription factor A, mitochondrial (TFAM) is also a selective target of 4E-BP-mediated 
translation, suggesting that these components may function in a common pathway targeted by 
mTOR (Morita et al., 2013). Regardless of the precise mechanism, our data establish MTFP1 as 
an essential regulator of mitochondrial fission through the modulation of DRP1 phosphorylation 
and recruitment. The S616 phosphorylation of DRP1 is controlled by many kinases that depend 
on the cellular context, most notably ERK1/2 within RAS-induced tumors (Kashatus et al., 2015; 
Prudent and McBride, 2017; Serasinghe et al., 2015). mTORC1 signaling, which is aberrantly 
activated in many cancers, has also been linked to the ERK1/2 kinases (Chen et al., 2010; Mendoza 
et al., 2011). Further work will focus on identifying the molecular signals that link MTFP1 function 
within the inner membrane and the kinases that regulate phosphorylation of DRP1 downstream of 
the mTORC1/4E-BP/MTFP1 axis. 
Mitochondrial morphology varies across cell types and tissues in physiological and 
pathological conditions (Friedman and Nunnari, 2014; Vyas et al., 2016). A major challenge has 
been to understand the molecular mechanisms that couple intracellular and environmental stimuli 
to mitochondrial dynamics. asTORi treatment induced a mitochondrial elongation phenotype, 
similar to what occurs during starvation (Gomes et al., 2011; Rambold et al., 2011). We previously 
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characterized a series of specific 4E-BP specific targets that function to lower mitochondrial 
metabolism, including reductions in components of the ETC and ATP synthase, subunits of the 
mitochondrial ribosome, TFAM and others (Morita et al., 2013). In addition, those studies revealed 
a nearly 40% reduction in mtDNA levels upon asTORi treatment. Together with evidence 
presented here revealing a direct link to mitochondrial morphology and survival, this underscores 
mitochondrial metabolism as a major target of the adaptive response to mTOR inhibition. This is 
in sharp contrast to response seen upon mitochondrial dysfunction, where fragmentation and 
mitophagy are fully activated (Toyama et al., 2016). Precipitous reductions in cellular ATP 
through inhibition of the ETC was recently shown to damage mitochondria and activate AMP-
activating protein kinase (AMPK), leading to direct phosphorylation of the DRP1 receptor MFF 
(Toyama et al., 2016). This resulted in highly fragmented mitochondria, which were then cleared 
by mitophagy (Toyama et al., 2016). Indeed, mitochondrial damage is a requisite for stalled PINK1 
import, Parkin recruitment and mitophagy (Pickrell and Youle, 2015). Our data show that 
inhibition of mTORC1 does not trigger mitochondrial dysfunction directly, explaining why 
mitophagy is not programmed in this pathway.  
mTOR signaling is hyper-activated in many cancers and promotes growth and 
proliferation (Benjamin et al., 2011; Bhat et al., 2015; Kim et al., 2016; Zoncu et al., 2011); thus,   
asTORi are currently being tested in phase I/II clinical trials (Basu et al., 2015; Bendell et al., 
2015; Naing et al., 2012). A major challenge concerning the therapeutic inhibition of mTOR is the 
potential for compensatory mechanisms that increase survival of cancer cells (Benjamin et al., 
2011). In this study, we provide evidence that the suppression of mTORC1 activity by active-site 
inhibitors reduces the translation of MTFP1, leading to the altered phosphorylation and 
localization of DRP1, a marked hyperfusion response and enhanced cell survival. Hence, the well-
established anti-proliferative effects of asTORi are compensated by a protective effect of cell 
survival through reduction in MTPF1 levels. Importantly, uncoupling MTFP1 levels from the 4E-
18 
 
BP-mediated regulation upon mTOR inhibition leads to apoptosis (Figure 7), demonstrating that 
translational control of MTFP1 by mTORC1/4E-BP acts as a critical determinant of cell fate. 
mTOR inhibitors are generally cytostatic and thus cannot be expected to act as potent anti-cancer 
drugs.  Our results offer a new therapeutic strategy to maintain the pro-fission state in asTORi-
based therapy, and thus promote cancer cell death.  
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FIGURE LEGENDS 
Figure 1. Active-site mTOR inhibitor induces mitochondrial elongation, branching and 
circularization. 
(A-B) Representative transmission electron microscopy (TEM) images of wild-type (WT) MEFs 
treated with vehicle (DMSO) (A) or Ink1341 (200 nM) (B) for 24 hr showing well-preserved 
mitochondria (Mito) and endoplasmic reticulum (ER) in (A), but elongated, branched and 
circularized mitochondria, ER and autophagosomes (AP) in (B). Scale bars represent 1 Pm. 
(C-H) Quantification of TEM images of WT MEFs treated with vehicle or Ink1341 for 24 hr 
showing mitochondrial length (C), percentage of branched mitochondria (D), mitochondrial 
number per 100 Pm2 of cytoplasmic area (E), mitochondrial area per cytoplasmic area (F), 
autophagosome area per cytoplasmic area (G) and distribution of mitochondrial length (H). Data 
are shown as 0 to 100% box plots with the 25th, 50th, and 75th percentiles as the lower, middle, 
and upper boundaries of the box, respectively. For (C, D, H), n = 1544 mitochondria for vehicle, 
n = 987 for Ink1341 from three independent experiments. For (E-G), n = 30 cells per group from 
three independent experiments. *P < 0.05, **P <0.01, ***P < 0.001; Student’s t test. 
(I-J) Focused Ion Beam-Scanning Electron Microscopy (FIB-SEM) 3-D visualization of WT 
MEFs treated with vehicle (I) or Ink1341 (200 nM) (J) for 24 hr showing mitochondria (Mito), ER 
and autophagosomes (AP). Scale bars represent 1 Pm. 
See also Figures S1 and S2. 
 
Figure 2. Alterations in localization of DRP1 and protein levels of mitochondrial fission 
factors in asTORi-treated cells. 
(A) Representative confocal images of mitochondrial morphology in wild-type (WT) MEFs treated 
with vehicle or Ink1341 (200 nM) for 24 hr. Mitochondria were labeled using an anti-TOM20 
antibody. * indicates cells with elongated/branched mitochondria. Scale bars represent 20 Pm. 
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(B) Quantification of mitochondrial morphology in WT MEFs treated with vehicle or Ink1341 
(200 nM) for 24 hr (left). n = 303 for vehicle, n = 261 for Ink1341 from three independent 
experiments. Data represent mean ± SD. ***P < 0.001; Student’s t test. Representative confocal 
images of cells with the indicated mitochondria (right). 
(C) Representative images of mitochondrial morphology and DRP1 localization in MEFs treated 
with vehicle (upper) or Ink1341 (lower) for 24 hr. Mitochondria and DRP1 were stained with anti-
TOM20 and anti-DRP1 antibodies, respectively. Scale bars represent 10 Pm. 
(D) Levels of DRP1, TOM20 and D-tubulin proteins in subcellular fractions from MEFs treated 
with vehicle or Ink1341 (200 nM) for 24 hr. Total cell lysates (Total) were fractionated into 
mitochondrial (Mito) and cytosolic (Cyto) fractions. 
(E) Levels of proteins relevant to mitochondrial fission and fusion, mTORC1 signaling and 
autophagy in MEFs treated with Ink1341 (200 nM) for the indicated time. D-tubulin and E-actin 
were used as loading controls. Quantification of levels of the indicated proteins is shown in Figure 
S2C. 
See also Figures S1 and S2. 
 
Figure 3. mTORC1-dependent regulation of mitochondrial dynamics. 
(A-B) Representative images of mitochondrial morphology and DRP1 localization in raptor wild-
type (WT) and knockout (KO) MEFs (A), or rictor WT and KO MEFs (B). Mitochondria and 
DRP1 were stained with anti-TOM20 and anti-DRP1 antibodies, respectively. Scale bars represent 
10 Pm. 
(C) Quantification of mitochondrial morphology in raptor WT and KO MEFs, or rictor WT and 
KO MEFs. n = 322 for raptor WT, n = 290 for raptor KO, n = 247 for rictor WT, n = 266 for rictor 
KO from three independent experiments. Data represent mean ± SD. **P <0.01; Student’s t test. 
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Representative confocal images of mitochondrial morphology in raptor WT and KO, or rictor WT 
and KO MEFs are shown in Figures S3A-B. 
(D-E) Levels of proteins relevant to mitochondrial fission and fusion and mTORC1 signaling in 
raptor WT and KO MEFs (D), or rictor WT and KO MEFs (E). D-tubulin and E-actin were used 
as loading controls. Quantification of levels of the indicated proteins is shown in Figure S3C. 
See also Figure S3. 
 
Figure 4. mTORC1 activation by TSC2 deletion induces mitochondrial fragmentation. 
(A) Levels of the indicated proteins in TSC2 wild-type (WT) and knockout (KO) MEFs. D-tubulin 
was used as a loading control. Quantification of levels of the indicated proteins is shown in Figure 
S3D. 
(B) Representative confocal images of mitochondrial morphology in TSC2 WT and KO MEFs. 
Mitochondria were labeled using an anti-TOM20 antibody. ** indicates cells with fragmented 
mitochondria. Scale bars represent 20 Pm. 
(C) Quantification of mitochondrial morphology in TSC2 WT and KO cells. n = 191 for TSC2 
WT, n = 226 for TSC2 KO from three independent experiments. Data represent mean ± SD. *P < 
0.05, **P <0.01; Student’s t test. 
See also Figure S3. 
 
Figure 5. 4E-BPs mediate mTORC1-dependent mitochondrial fission. 
(A-B) Representative TEM images of 4E-BP1/2 double knockout (4E-BP DKO) MEFs treated 
with vehicle (A) or Ink1341 (200 nM) (B) for 24 hr showing mitochondria (Mito), endoplasmic 
reticulum (ER) and autophagosomes (AP). Scale bars represent 1 Pm. Representative TEM images 
of 4E-BP1/2 wild-type (4E-BP WT) MEFs treated with vehicle or Ink1341 are shown in Figures 
S4A-B. 
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(C-F) Quantification of TEM images of 4E-BP WT and 4E-BP DKO MEFs treated with vehicle 
or Ink1341 (200 nM) showing mitochondrial length (C), percentage of branched mitochondria (D), 
mitochondrial area per cytoplasmic area (E) and autophagosome area per cytoplasmic area (F). 
Data are shown as 0 to 100% box plots with the 25th, 50th, and 75th percentiles as the lower, 
middle, and upper boundaries of the box, respectively. For (C-D), n = 810 for WT + vehicle, n = 
504 for WT + Ink1341, n = 691 for DKO + vehicle, n = 719 for DKO + Ink1341 from three 
independent experiments. For (E-F), n = 30 cells per group from three independent experiments. 
*P < 0.05, **P <0.01, ***P < 0.001; two-way ANOVA with Tukey’s post-hoc test. 
(G) Quantification of mitochondrial morphology by confocal microscopy in 4E-BP WT and DKO 
MEFs treated with vehicle or Ink1341 (200 nM) (top). Mitochondria were labelled with an anti-
TOM20 antibody. Data represent mean ± SD. n = 333 for WT + vehicle; n = 261 for WT + Ink1341; 
n = 315 for DKO + vehicle; n = 333 for DKO + Ink1341 from three independent experiments. 
***P < 0.001; Student’s t test. Representative confocal images of cells with the indicated 
mitochondria (bottom). 
(H) Representative images of mitochondrial morphology and DRP1 localization in 4E-BP1/2 DKO 
MEFs treated with vehicle (left) or Ink1341 (right). Mitochondria and DRP1 were stained with 
anti-TOM20 and anti-DRP1 antibodies, respectively. Scale bars represent 10 Pm. 
See also Figures S5 and S6. 
 
Figure 6. Translational control of MTFP1 by the mTORC1/4E-BP signaling pathway. 
(A) Polysome profiles of 4E-BP1/2 wild-type (4E-BP WT) MEFs treated with vehicle or Ink1341 
(200 nM) for 12 hr. Absorbance at 254 nm was recorded continuously. 40S, 60S and 80S denote 
the positions of corresponding ribosomal subunits and monosomes. 
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(B) Distribution of Mtfp1, CyclinD3 and E-actin mRNAs in polysome profiles from (A) was 
determined by RT-qPCR. Data represent mean ± SD. A representative experiment of two 
independent experiments (each carried out in triplicate) is presented. 
(C) Polysome profiles of 4E-BP1/2 double knockout (4E-BP DKO) MEFs treated with vehicle or 
Ink1341 (200 nM) for 12 hr. Absorbance at 254 nm was recorded continuously. 40S, 60S and 80S 
denote the positions of corresponding ribosomal subunits and monosomes. 
(D) Distribution of Mtfp1, CyclinD3 and E-actin mRNAs in polysome profiles from (C) was 
determined by RT-qPCR. Data represent mean ± SD. A representative experiment of two 
independent experiments (each carried out in triplicate) is presented. 
(E) Levels of proteins relevant to mitochondrial fission, mTORC1 signaling and autophagy in 4E-
BP WT and DKO MEFs treated with vehicle or Ink1341 for 24 hr. D-tubulin was used as a loading 
control. Quantification of levels of the indicated proteins is shown in Figure S4G. 
See also Figures S5 and S6. 
 
Figure 7. Translational regulation of mitochondrial fission and cell survival by the 
mTORC1/4E-BP/MTFP1 signaling axis. 
(A) Levels of proteins relevant to mitochondrial fission and mTORC1 signaling in empty vector 
(control) and MTFP1-overexpressing (MTFP1) MEFs treated with vehicle or Ink1341 (200 nM) 
for 24 hr. D-tubulin was used as a loading control. Quantification of levels of the indicated proteins 
is shown in Figure S8A. 
(B) Representative confocal images of mitochondrial morphology in control and MTFP1-
overexpressing MEFs treated with vehicle or Ink1341 (200 nM) for 24 hr. Mitochondria were 
labeled using an anti-TOM20 antibody. Scale bars represent 20 Pm. * and ** indicate cells with 
elongated and fragmented mitochondria, respectively. 
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(C) Quantification of mitochondrial morphology in control and MTFP1-overexpressing MEFs 
treated with vehicle or Ink1341 (200 nM) for 24 hr. n = 179 for control + vehicle, n = 115 for 
control + Ink1341, n = 213 for MTFP1 + vehicle, n = 173 for MTFP1 + Ink1341 from three 
independent experiments. Data represent mean ± SD. **P <0.01, ***P < 0.001; Student’s t test. 
(D-E) Cell proliferation was assayed by 5-bromo-2’-deoxyuridine (BrdU) incorporation (D) or 
Giemsa staining (E). BrdU incorporation was measured in control and MTFP1-overexpressing 
MEFs treated with vehicle, Ink1341 (200 nM) or Ink128 (200 nM) for 48 hr (D). Data represent 
mean ± SEM. A representative experiment of three independent experiments (each carried out in 
n = 5) is presented. Control and MTFP1-overexpressing MEFs were treated with the indicate drug 
and visualized with Giemsa staining (E). *P < 0.05; two-way ANOVA with Tukey’s post-hoc test. 
(F) Caspase-3/7 activity in cells (D-E) was measured by a fluorometric caspase-3/7 activity assay. 
Data represent mean ± SEM. A representative experiment of two independent experiments (each 
carried out in n = 6) is presented. ***P < 0.001; two-way ANOVA with Tukey’s post-hoc test. 
See also Figures S6 and S7. 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents may be directed to the Lead Contact, Nahum 
Sonenberg (nahum.sonenberg@mcgill.ca) 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell Lines and Cell Culture Conditions 
Cells were maintained in DMEM containing 10% FBS and 100 units/ml 
penicillin/streptomycin (all from Invitrogen) at 37oC and 5% CO2. WT (p53-/-) and 4E-BP DKO 
(p53-/-) MEFs were described (Petroulakis et al., 2009). Inducible raptor and rictor KO MEFs were 
described (Cybulski et al., 2012; Robitaille et al., 2013). TSC2 WT (p53-/-) and KO (p53-/-) MEFs 
were described (Zhang et al., 2003). A375 cells were obtained from ATCC (CRL-1619). Cells 
were seeded at ~20% confluency, grown overnight and treated with vehicle (DMSO), Ink1341 
(200 nM), Ink128 (200nM), Torin1 (200 nM), rapamycin (200 nM) and PMA (100 nM) for 24 hr 
or the indicated time. 
 
METHOD DETAILS 
Transmission Electron Microscopy 
MEFs (70% confluency) treated with vehicle (DMSO), Ink1341 (200 nM) or rapamycin 
(200 nM) for 24 hr were washed with PBS 3 times each for 1 minute (min) and fixed with 100 mM 
sodium cacodylate buffer containing 2.5% glutaraldehyde (pH 7.4) for 2 hr at 4°C. Samples were 
washed 3 times each for 1 min with sodium cacodylate buffer containing 5% sucrose (pH 7.4) at 
4°C, followed by osmification with 2% OsO4 in sodium cacodylate buffer containing 3% 
potassium ferrocyanide and 5% sucrose for 2 hr at 4°C. This was followed by washing 3 times 
each for 1 min with sodium cacodylate buffer containing 5% sucrose (pH 7.4). Samples were then 
stained with sodium cacodylate buffer containing 1% tannic acid and 5% sucrose for 1 hr at 4°C. 
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The solution was replaced by sodium cacodylate buffer containing 1% sodium sulfate and 5% 
sucrose for 20 min at 4°C. This solution was further replaced by 100 mM sodium maleate (pH 5.7) 
for 10 min, followed by sodium maleate buffer containing 6% uranyl acetate (pH 5.7) for 2 hr at 
4°C. Samples were washed with sodium maleate buffer (pH 5.7) 3 times each for 1 min. Samples 
were dehydrated through graded alcohols (50%-100%) at room temperature (RT), followed by 
embedding in epoxy resin diluted 1:1 with 100% alcohol for 1 hr and 100% epoxy for 1 hr, 
followed by 2 hr in a desiccated vacuum container and overnight polymerization at 65°C. Blocks 
were trimmed and cut at 90 to 100 nm thick with an UltraCut E ultramicrotome (Reichert-Jung). 
Serial sections were transferred onto a 200-mesh Cu grid, and poststained with 4% uranyl acetate 
for 8 min and then with Reynold's lead for 5 min. Cells on the grids were observed with a 
transmission EM (FEI Tecnai 12; FEI) operated at 120 kV, and images were collected with a CCD 
camera (AMT XR 80 C). For quantification analysis, low-magnification EM images of the cells 
were taken. On these images, all mitochondria, ER and autophagosomes were identified manually 
using Adobe Photoshop software. The length and area of each mitochondrion and autophagosome, 
as well as the total cytoplasmic area of each cell, were measured (Photoshop software). Data are 
shown as 0 to 100% box plots with the 25th, 50th, and 75th percentiles as the lower, middle, and 
upper boundaries of the box, respectively, from three independent experiments. 
 
Focused Ion Beam-Scanning Electron Microscope  
Sample blocks for 3-D characterization by FIB-SEM were prepared as described above 
for TEM. Each trimmed Epon block was mounted on a 45° pre-titled SEM stub and coated with a 
2 nm platinum layer to enhance electrical conductivity. Milling of serial sections and imaging of 
block face after each z-slice was carried out with the FEI Helios Nanolab 660 DualBeam (FEI Co., 
Hillsboro, OR USA) using the FEI Auto Slice & View G3 ver 1.4 software 
(http://www.fei.com/software/auto-slice-and-view).  
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A block was first imaged to determine the orientation relationship between the block face 
and ion and electron beams. In the experiments, theta (Ө), the angle between the block face and 
the 45° pre-titled SEM stub, was found to be -13°. A protective carbon layer 20-µm long, 5-µm 
wide and 2-µm thick was deposited on the surface of the region that contained cells without bias 
to protect the resin volume and correct for stage and/or specimen drift, i.e. perpendicular to the 
image face of the volume to be milled. Trenches on either side of the region were created to 
minimize re-deposition during the automated milling and imaging. Imaging fiducial was generated 
for both ion beam and electron beam imaging and used to dynamically correct for specimen and 
stage drift. Milling was performed at 30 kV with an ion beam current of 0.79 nA, stage tilt of -6°, 
working distance of 4 mm, and increments of 4 nm in the Z-direction. Each newly milled block 
face was imaged with the solid-state, high energy in-column detector (ICD) for backscattered 
electrons at an accelerating voltage of 2 kV, beam current of 0.4 nA, stage tilt of 32°, and working 
distance of 2.5 mm. The pixel resolution was 3.4 nm (X-direction) by 3.4 nm (Y-direction) with a 
dwell time of 30 µs. Pixel dimensions of the recorded image were 3072 x 2048 pixels. One hundred 
and eighty images were collected for each block and the contrast of the images inversed. 
Visualization and direct 3-D volume rendering of the acquired datasets was performed with Amira 
6.0.1 software (http://www.fei.com/software/amira-3d-for-life-sciences; FEI Co., Hillsboro, OR 
USA) with 30 successive images selected based on the region of interest, i.e., mitochondria. 
 
Immunofluorescence 
Immunofluorescence were performed as previously described (Prudent et al., 2015). 
Briefly, cells were fixed in 5 % paraformaldehyde (PFA) (Sigma) in PBS at 37°C for 15 min, then 
washed 3 times with PBS, followed by quenching with 50 mM ammonium chloride in PBS. After 
3 washes in PBS, cells were permeabilized in 0.1 % Triton X-100 (Sigma) in PBS, followed by 3 
washes in PBS. Then cells were blocked with 10 % fetal bovine serum (FBS) in PBS, followed by 
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incubation with primary antibodies in 5 % FBS in PBS, for 1 hr at RT. After 3 washes with 5 % 
FBS in PBS, cells were incubated with Alexa fluor 488, 594 or 647, secondary antibodies (1:1000) 
(Invitrogen) for 1 hr at RT. After 3 washes in PBS, coverslips were mounted onto slides using 
Dako fluorescence mounting medium (Dako).  
Stained cells were imaged using a 60X or a 100X objective lenses (NA1.4) on an Olympus 
IX81 inverted microscope with appropriate lasers using an Andor/Yokogawa spinning disk system 
(CSU-X), with a sCMOS camera, coupled with the MetaMorph software. For mitochondrial 
morphology analysis, 1-3 stacks of 0.2-0.4 μm each were acquired using the 60X objective. Images 
were then compiled by “max projection” and mitochondrial morphology was analyzed and 
presented as intermediate, elongated or fragmented. For DRP1 analysis, a 0.2 μm z axis image 
series (5-7 stacks) of cells labelled for TOM20 and DRP1 were obtained using the 100X objective 
and stacked in the same condition of gain, laser intensities and exposure time. Images were then 
compiled as “Max projection” and analyzed using the FIJI software. 
 
mTOR inhibitors, lentivirus infection, siRNA and GFP-DRP1 plasmid transfection  
Ink1341 and Ink128 were provided by Intellikine. Torin1 and rapamycin were purchased 
from Tocris Bioscience. PMA was purchased from EMD Millipore Corporation. 
For lentivirus production, lentiviral vectors were co-transfected into HEK293T cells with 
the lentivirus packaging plasmids PLP1, PLP2 and PLP-VSVG (Invitrogen) using Lipofectamine 
2000 (Invitrogen). Supernatants were collected 48 hr post infection, passed through a 0.45 Pm 
nitrocellulose filter, and applied on target cells with polybrene (1 Pg/ml). Cells were selected with 
puromycin (5 Pg/ml) for 48 hr. Lentiviral vectors encoding MTFP1 (EX-T9261-Lv105 and EX-
T9261-Lv151) cDNAs were obtained from GeneCopoeia. 
For small interference (si) RNA experiments, cells were transfected using Lipofectamine 
RNAimax (Invitrogen) with 20 nM siRNA for 3 days. A control siRNA (Silencer Selected 
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Negative Control siRNA, Invitrogen) was used for each experiment. To silence MTFP1, TSC2 
WT and KO cells were transfected with siRNA against MTFP1 (Silencer Selected Pre-Designed 
siRNA against MTFP1 s85882, Invitrogen). For transient transfection of GFP-DRP1 plasmids, 
MEFs were transfected using Lipofectamine 3000 reagent (Invitrogen) according to the 
manufacturer’s recommendations. 
 
CRISPR-mediated gene knockout 
A375 cells were transfected in 6 well plates with a plasmid expressing hCas9 (Addgene 
plasmid #41815) (0.7 Pg); gRNA targeting 4E-BP1 (purchased from GeneCopoeia, cat. # 
HCP204676-SG01-3-B-a; HCP204676-SG01-3-B-b; and HCP204676-SG01-3-B-c against 4E-
BP1 sequences CCGCCCGCCCGCTTATCTTC; GTGAGTTCCGACACTCCATC; and 
TGAAGAGTCACAGTTTGAGA, respectively); gRNA targeting 4E-BP2 (purchased from 
GeneCopoeia, cat. # HCP254214-SG01-3-B-a; HCP254214-SG01-3-B-b; and HCP254214-
SG01-3-B-c against 4E-BP2 sequences GTGGCCGCTGCCGGCTGACG; 
CTAGTGACTCCTGGGATATT; and ACAACTTGAACAATCACGAC) (0.2 Pg for each gRNA 
to total 1.2 Pg); and pBabe-puro (0.6 Pg), using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. A plasmid expressing hCas9 was gifted from George Church 
(Addgene plasmid #41815) (Mali et al., 2013). As a control, cells were transfected with a plasmid 
expressing hCas9 (0.7 Pg) and pBabe-puro (0.6 Pg), using Lipofectamine 2000 (Invitrogen). Two 
days post-transfection, cells were selected for 3 days with puromycin (4 Pg/ml) to remove non-
transfected cells. Following selection, cells were seeded in 96 well plates at a density of single 
cell/well in puromycin free media. Cells were monitored to the presence of single colonies/well. 
Single cell colonies were amplified to generate cell lines and the expression of 4E-BP1 and 4E-
BP2 was analysed by western blot. Lines with loss of 4E-BP1 and 4E-BP2 expression were kept 
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for further experiments. For the control cells, single cell colonies were amplified and 5 of the 
control lines were pooled to generate the A375 CRISPR control population.   
 
BrdU incorporation, Giemsa staining, caspase-3/7 activity assay 
Empty vector (control) and MTFP1-expressing cells (5 x 103) were seeded in a 96-well 
plate and treated with the indicated drugs in the figure legend. Cell proliferation rate was 
determined using Cell Proliferation Elisa BrdU kit (Roche). Absorbance at 370 nm (reference 
wavelength 492 nm) was measured using a Varioskan microplate reader (Thermo Fisher 
Scientific). Empty vector (control) and MTFP1-expressing cells (1.5 x 105) were seeded in a 6-
well plate, treated with the indicated drugs for 48 hr and visualized with Giemsa staining. Caspase-
3/7 activity was determined using Caspase Glo 3/7 Assay (Promega). Luminescence was measured 
using GloMax 96 Microplate Luminometer (Promega). 
 
Cell lysis, Western blotting, antibodies 
Cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 
1% NP-40, Roche complete protease inhibitor cocktail). Protein concentrations were determined 
with the Bio-Rad protein assay (Bio-Rad). Proteins were resolved by SDS-PAGE, and then 
transferred to PVDF membranes. Antibodies against phospho-DRP1 (S616) (#3455), phospho-
DRP1 (S637) (#4867), 4E-BP1 (#9644), phospho-4E-BP1 (T37/46) (#2855), phospho-4E-BP1 
(S65) (#9456), phospho-S6K (T389) (#9234), mTOR (#2983), ATG5 (#8540), LC3 (#4599), 
PARP (#9532), MFN1 (#14739) and D-tubulin (#2144) were from Cell Signaling Technology. 
Antibodies against MFN2 (sc-100560), S6K1 (sc-230), TOM20 (sc-11415) and TSC2 (sc-893) 
were from Santa Cruz Biotechnology Inc. Antibodies against DRP1 (611113) and OPA1 (612606) 
were from BD Biosciences. MTFP1 (ab198217), rictor (A300-459), raptor (09-217) and β-actin 
(A5441) were from Abcam, Bethyl Laboratories Inc., EMD Millipore Corporation and Sigma-
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Aldrich Co., respectively. Horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG 
were from Amersham Biosciences (Baie d’Urfé). For immunofluorescence, goat anti-mouse and 
goat anti-rabbit Alexa Fluor 488, 597 or 647 were used as secondary antibodies (Invitrogen). 
 
Polysome profiling, RNA isolation, RT-qPCR 
Polysome profiling and RT-qPCR were carried out as described previously (Gandin et 
al., 2014). Briefly, cells were cultured in 15-cm dishes, treated with vehicle or Ink1341 (200 nM) 
for 12 hr, incubated in growth media containing 100 Pg/ml cycloheximide for 5 min at 37°C, 
washed twice with cold PBS containing 100 Pg/ml cycloheximide, collected and lysed in 450 Pl 
of hypotonic buffer (5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 mM KCl, 100 Pg/ml 
cycloheximide, 2 mM DTT, 0.5% Triton X-100 and 0.5% sodium deoxycholate). Lysates were 
loaded onto 10-50% (wt/vol) sucrose density gradients (20 mM HEPES-KOH (pH 7.6), 100 mM 
KCl and 5 mM MgCl2) and centrifuged at 35,000 rpm (SW 40 Ti rotor, Beckman Coulter, Inc.) 
for 2 hr at 4°C. Gradients were fractionated, and optical density at 254 nm was continuously 
recorded using an ISCO fractionator (Teledyne ISCO). RNA from each fraction and input was 
isolated using Trizol (Invitrogen) and GlycoBlue (Invitrogen) according to the manufacturer’s 
instructions. RT-qPCR reactions were carried out using SuperScript III First-Strand Synthesis 
System (Invitrogen) and iQ SYBR Green Supermix (Bio-Rad) according to the manufacturer’s 
instructions. Following primers were used: Mtfp1-forward 5’-TAATCCACCCCATCGACAG-3’ 
and Mtfp1-reverse 5’-TCCACTGACGGGTACAGCTT-3’. Primers for cyclin D3 and E-actin 
mRNAs were previously described (Dowling et al., 2010). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Quantification of Immunoblottings 
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For all quantification of band intensities, ImageJ software was used 
(https://imagej.nih.gov/ij/index.html). 
 
Statistical analysis 
Data represent mean ± SD or SEM, or are shown as 0 to 100% box plots with the 25th, 
50th, and 75th percentiles as the lower, middle, and upper boundaries of the box, respectively. 
Differences among groups were compared using two-way ANOVA followed by between-group 
comparison with Tukey’s post-hoc test, or Student’s t-test (two-tailed, unpaired) when there were 
only two groups. All statistical analyses were performed using IBM SPSS Statistics Version 22 
software. The differences were considered significant when *P < 0.05, **P <0.01 and ***P < 
0.001. Statistical results, along with tests used, were summarized in Table S1. 
 
DATA AND SOFTWARE AVAILABILITY 
The original, unprocessed data have been deposited to Mendeley Data and are available 
at http://dx.doi.org/10.17632/mjfjdvvw75.1. 
 
 KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal phospho-DRP1 (S616) 
antibody 
Cell Signaling Technology 3455 
Rabbit polyclonal phospho-DRP1 (S637) 
antibody 
Cell Signaling Technology 4867 
Mouse monoclonal DRP1 antibody BD Biosciences Laboratories 611113 
Rabbit monoclonal phospho-4E-BP1 (T37/46) 
(236B4) antibody 
Cell Signaling Technology 2855 
Rabbit monoclonal phospho-4E-BP1 (S65) 
(174A9) antibody 
Cell Signaling Technology 9456 
Rabbit monoclonal 4E-BP1 (53H11) antibody Cell Signaling Technology 9644 
Rabbit polyclonal 4E-BP2 antibody Cell Signaling Technology 2845 
Rabbit monoclonal phospho-S6K (T389) 
antibody 
Cell Signaling Technology 9234 
Rabbit polyclonal S6K1 antibody Santa Cruz Biotechnology sc-230 
Rabbit monoclonal phospho-S6 Ribosomal 
Protein (Ser240/244) (D68F8) antibody 
Cell Signaling Technology 5364 
Mouse monoclonal S6 ribosomal protein 
antibody 
Santa Cruz Biotechnology sc-74459 
Rabbit monoclonal mTOR (7C10) antibody Cell Signaling Technology 2983 
Rabbit monoclonal phospho-eIF4E (S209) 
antibody 
Abcam ab76256 
Mouse monoclonal eIF4E antibody BD Biosciences 610270 
Rabbit polyclonal MTFP1 antibody Abcam ab198217 
Rabbit monoclonal MFN1 (D6E2S) antibody Cell Signaling Technology 14739 
Rabbit polyclonal MFF antibody Cell Signaling Technology 86668 
Rabbit monoclonal ATG5 (D5F5U) antibody Cell Signaling Technology 12994 
Rabbit monoclonal LC3A (D50G8) antibody Cell Signaling Technology 4599 
Rabbit monoclonal PARP (46D11) antibody Cell Signaling Technology 9532 
Rabbit polyclonal D-tubulin antibody Cell Signaling Technology 2144 
Mouse monoclonal MFN2 (XX-1) antibody Santa Cruz Biotechnology Inc. sc-100560 
Rabbit polyclonal TOM20 (FL-145) antibody Santa Cruz Biotechnology Inc. sc-11415 
Rabbit polyclonal TSC2 (C-20) antibody Santa Cruz Biotechnology Inc. sc-893 
Mouse monoclonal OPA1 antibody BD Biosciences 612606 
Rabbit polyclonal rictor antibody Bethyl Laboratories Inc. A300-459 
Rabbit polyclonal raptor antibody EMD Millipore Corporation  09-217 
Mouse monoclonal β-actin antibody Sigma-Aldrich Co. A5441 
Rabbit polyclonal GFP antibody MBL Co. 598 
Anti-rabbit IgG, horseradish peroxidase (HRP)-
linked Antibody 
Cell Signaling Technology 7074 
Anti-mouse IgG, horseradish peroxidase (HRP)-
linked Antibody 
Cell Signaling Technology 7076 
Goat anti-mouse IgG (H+L) secondary antibody, 
Alexa Fluor 488  
Invitrogen A-11029 
F(ab')2-goat anti-rabbit IgG (H+L) secondary 
antibody, Alexa Fluor 488 
Invitrogen A-11070 
Key Resource Table
 Goat anti-mouse IgG (H+L) secondary antibody, 
Alexa Fluor 594 
Invitrogen  A-11005 
Goat anti-rabbit IgG (H+L) secondary antibody, 
Alexa Fluor 594 
Invitrogen A-11012 
Goat anti-mouse IgG (H+L) secondary antibody, 
Alexa Fluor 647 
Invitrogen A-21235 
Goat anti-rabbit IgG (H+L) secondary antibody, 
Alexa Fluor 647 
Invitrogen A-21244 
Plasmids  
pCRISPR-SG01-3 (3 x sgRNA targeting 4E-
BP1) 
GeneCopoeia HCP204676-SG01-3 
pCRISPR-SG01-3 (3 x sgRNA targeting 4E-
BP2) 
GeneCopoeia HCP254214-SG01-3 
pCas9 Addgene (Mali et al., 2013) 41815 
Lenti-Pac HIV Expression Packaging Kit GeneCopoeia LT001 
pReceiver-Lv105-empty control GeneCopoeia EX-NEG-Lv105 
pReceiver-Lv105-MTFP1 GeneCopoeia EX-T9261-Lv105 
pReceiver-Lv151-empty control GeneCopoeia EX-NEG-Lv151 
pReceiver-Lv151-MTFP1 GeneCopoeia EX-T9261-Lv151 
pEGFP-N1-DRP1 WT (Cribbs and Strack, 2007) N/A 
pEGFP-N1-DRP1 S616D (Cribbs and Strack, 2007) N/A 
pEGFP-N1-DRP1 S637A (Cribbs and Strack, 2007) N/A 
pEGFP-N1-DRP1 S616D/S637A (Cribbs and Strack, 2007) N/A 
Chemicals 
Ink1341 Gifted from Intellikine N/A 
Ink128 Cayman chemical 11811 
Torin1 Tocris Bioscience 4247 
Rapamycin Tocris Bioscience 1292 
PMA EMD Millipore Corporation 524400 
Critical Commercial Assays 
Cell Proliferation Elisa BrdU (colorimetric) Roche 11647229001 
Caspase Glo 3/7 Assay Systems Promega corporation G8093 
Deposited Data 
Raw image data This paper Mendeley data: 
http://dx.doi.org/10.17
632/mjfjdvvw75.1 
Experimental Models: Cell Lines 
WT (p53-/-) and 4E-BP DKO (p53-/-) MEFs (Petroulakis et al., 2009) N/A 
Inducible raptor WT and KO MEFs (Cybulski et al., 2012) N/A 
Inducible rictor WT and KO MEFs (Cybulski et al., 2012) N/A 
TSC2 WT (p53-/-) and KO (p53-/-) MEFs (Zhang et al., 2003) N/A 
A375 cells ATCC CRL-1619 
WT (p53-/-) MEFs expressing MTFP1 This paper N/A 
Inducible raptor KO MEFs expressing MTFP1 This paper N/A 
Oligonucleotides 
Silencer Select Negative Control No. 1 siRNA Invitrogen 4390843 
Silencer Select Pre-Designed siRNA against 
MTFP1 (siRNA ID: s85882) 
Invitrogen 4390771 
qPCR primer: Mtfp1 forward: 
TAATCCACCCCATCGACAG 
This paper N/A 
 qPCR primer: Mtfp1 reverse: 
TCCACTGACGGGTACAGCTT 
This paper N/A 
qPCR primer: Cyclin D3 forward: 
CGAGCCTCCTACTTCCAGTG 
(Dowling et al., 2010) N/A 
qPCR primer: Cyclin D3 reverse: 
CCGAGCCTCCTACTTCCAGTG 
(Dowling et al., 2010) N/A 
qPCR primer: β-actin forward: 
GGCTGTATTCCCCTCCATCG 
(Dowling et al., 2010) N/A 
qPCR primer: β-actin forward: 
CCAGTTGGTAACAATGCCATGT 
(Dowling et al., 2010) N/A 
Software and Algorithms 
R The R Project for Statistical 
Computing 
N/A 
ImageJ NCBI https://imagej.nih.gov
/ij/index.html 
IBM SPSS Statistics Version 22 IBM N/A 
 
 
 
Figure 1. Morita et al.
Active-site mTOR inhibitor induces mitochondrial elongation, branching and circularization
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Figure 2. Morita et al.
Alterations in localization of DRP1 and protein levels of fission factors in asTORi-treated cells
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Figure S1, related to Figures 1 and 2. The effect of rapamycin on mitochondrial dynamics 
(A-B) Representative transmission electron microscopy (TEM) images of wild-type (WT) MEFs 
treated with vehicle (DMSO) (A) or rapamycin (200 nM) (B) for 24 hr showing well-preserved 
mitochondria (Mito) and endoplasmic reticulum (ER) in (A), but elongated mitochondria, ER and 
autophagosomes (AP) in (B). Scale bars represent 1 Pm. 
(C-D) Quantification of TEM images of WT MEFs treated with vehicle or rapamycin (200 nM) for 
24 hr showing mitochondrial length, percentage of branched mitochondria, mitochondrial number 
per 100 Pm2 of cytoplasmic area, autophagosome area per cytoplasmic area (C) and distribution 
of mitochondrial length (D). Data are shown as 0 to 100% box plots with the 25th, 50th, and 75th 
percentiles as the lower, middle, and upper boundaries of the box, respectively. For (C and D), n 
= 810 mitochondria for vehicle, n = 506 for rapamycin from three independent experiments. For 
mitochondrial number per 100 Pm2 of cytoplasmic area and autophagosome area per cytoplasmic 
area, n = 30 cells per group from three independent experiments. *P < 0.05, **P <0.01, ***P < 
0.001; Student’s t test. 
(E) Levels of proteins relevant to mitochondrial fission and fusion, mTORC1 signaling and 
autophagy in MEFs treated with vehicle, rapamycin (200 nM) and asTORis (200 nM) (Torin1 and 
Ink1341) for 24 hr. D-tubulin was used as a loading control. 
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Figure S2, related to Figures 1 and 2.
Figure S2, related to Figures 1 and 2. Active-site mTOR inhibitor induces mitochondrial 
elongation, branching and circularization 
(A-B) Back scattered image of a single xy plane of one slice (4 nm thickness) obtained by FIB-
SEM of WT MEFs treated with vehicle (A) and Ink1341 (200 nM) (B) for 24 hr showing well-
preserved mitochondria (Mito), endoplasmic reticulum (ER) and autophagosomes (AP) in (A), but 
branched and circularized Mito, ER and AP in (B). Scale bars represent 1 Pm. 
(C) Quantification of levels of the indicated proteins in Figure 2E. Signal intensities were quantified 
by densitometry and normalized with a DRP1 or D-tubulin level. n = 4 per group. Data represent 
mean ± SEM. *P <0.05, **P <0.01, ***P < 0.001; one-way ANOVA with Tukey’s post-hoc test. 
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Figure S3, related to Figure 3 and 4.
0
20
40
60
80
100
120
140
160
180
200
TSC2 WT TSC2 KO
0
20
40
60
80
100
120
0
20
40
60
80
100
120
140
0
20
40
60
80
100
120
140
160
180
200
pD
R
P1
(S
61
6)
/D
R
P1
(%
 o
f W
T)
pD
R
P1
(S
63
7)
/D
R
P1
(%
 o
f W
T)
D
R
P1
/α
-tu
bu
lin
(%
 o
f W
T)
M
TF
P1
/α
-tu
bu
lin
(%
 o
f W
T)
***
* * *
D
Figure S3, related to Figures 3 and 4. mTORC1-dependent regulation of mitochondrial 
dynamics 
(A-B) Representative confocal images of mitochondrial morphology in raptor WT and knockout  
(KO) (A), or rictor WT and KO (B) MEFs. Mitochondria were labeled using an anti-TOM20 antibody. 
Scale bars represent 20 Pm. * indicates cells with elongated mitochondria. 
(C) Quantification of levels of the indicated proteins in Figures 3D-E. Signal intensities were 
quantified by densitometry and normalized with a DRP1 or D-tubulin level. n = 6 per group. Data 
represent mean ± SEM. *P <0.05, **P <0.01, ***P < 0.001; Student’s t test. 
(D) Quantification of levels of the indicated proteins in Figure 4A. Signal intensities were quantified 
by densitometry and normalized with a DRP1 or D-tubulin level. n = 4 per group. Data represent 
mean ± SEM. *P <0.05, ***P < 0.001; Student’s t test. 
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Figure S4, related to Figures 5 and 6.
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Figure S4, related to Figures 5 and 6. 4E-BPs mediate mTORC1-dependent regulation of 
mitochondrial dynamics and MTFP1 translation 
(A-B) Representative TEM images of 4E-BP1/2 WT MEFs treated with vehicle (A) or Ink1341 
(200 nM) (B) for 24 hr showing well-preserved mitochondria (Mito) and endoplasmic reticulum 
(ER) in (A), but elongated, branched and circularized mitochondria, ER and autophagosomes 
(AP) in (B). Scale bars represent 1 Pm. 
(C) Quantification of TEM images of 4E-BP1/2 WT and double knockout (4E-BP DKO) MEFs 
treated with vehicle or Ink1341 (200 nM) for 24 hr, showing mitochondrial number per 100 Pm2 of 
cytoplasmic area. n = 30 cells per group from three independent experiments. Data are shown as 
0 to 100% box plots with the 25th, 50th, and 75th percentiles as the lower, middle, and upper 
boundaries of the box, respectively. 
(D) Distribution of mitochondrial length in 4E-BP WT (left) and DKO (right) MEFs treated with 
vehicle or Ink1341 (200 nM) for 24 hr. n = 810 for WT + vehicle, n = 504 for WT + Ink1341, n = 
691 for DKO + vehicle, n = 719 for DKO + Ink1341 from three independent experiments. 
(E) The genome-wide translational analysis demonstrated repression of the translational activity 
of Mtfp1 mRNA by asTORi (PP242) (1 PM) for 12 hr (Larsson et al., 2012). 
(F) Relative input levels of Mtfp1 and E-actin mRNAs in 4E-BP WT and DKO MEFs treated with 
vehicle or Ink1341 (200 nM) for 12 hr were quantified by RT-qPCR. Data represent mean ± SD. 
A representative experiment of two independent experiments (each carried out in triplicate) is 
presented. 
(G) Quantification of levels of the indicated proteins in Figure 6E. Signal intensities were quantified 
by densitometry and normalized with a DRP1 or D-tubulin level. n = 4 per group. Data represent 
mean ± SEM. *P <0.05, **P <0.01; two-way ANOVA with Tukey’s post-hoc test. 
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Figure S5, related to Figures 5 and 6.
Figure S5, related to Figures 5 and 6. The 4E-BP/eIF4E pathway mediates mTORC1-
dependent regulation of mitochondrial dynamics 
(A) Levels of the indicated proteins in WT MEFs treated with vehicle or PMA (100 nM) for 24 hr. 
E-actin was used as a loading control.  
(B) Representative confocal images of mitochondrial morphology in WT MEFs treated with vehicle 
or PMA (100 nM) for 24 hr. Mitochondria were labeled using an anti-TOM20 antibody. ** indicates 
cells with fragmented mitochondria. Scale bars represent 20 Pm. 
(C) Quantification of mitochondrial morphology in (B). n = 199 for vehicle, n = 225 for PMA from 
three independent experiments. Data represent mean ± SD. **P <0.01; Student’s t test. 
(D) Levels of the indicated proteins in 4E-BP WT and DKO A375 melanoma cells treated with 
vehicle or Ink1341 (200 nM) for 24 hr. E-actin was used as a loading control. 
(E) Representative confocal images of mitochondrial morphology in 4E-BP WT and DKO A375 
melanoma cells treated with vehicle or Ink1341 (200 nM) for 24 hr. Mitochondria were labeled 
using an anti-TOM20 antibody. * indicates cells with elongated mitochondria. Scale bars represent 
20 Pm. 
(F) Quantification of mitochondrial morphology in (E). Data represent mean ± SD. n = 298 for WT 
+ vehicle; n = 302 for WT + Ink1341; n = 372 for DKO + vehicle; n = 336 for DKO + Ink1341 from 
three independent experiments. . *P < 0.05, ***P < 0.001; Student’s t test. 
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Figure S6, related to Figure 7.
Figure S6, related to Figure 7. Effect of GFP-DRP1 phospho-mimetic/mutant 
overexpression on mitochondrial morphology 
(A) Levels of GFP proteins in WT MEFs transiently overexpressing empty vector (Mock), GFP-
DRP1-WT, -S616D, -S637A and double S616D/S637A. D-tubulin was used as a loading control. 
(B) Levels of GFP-DRP1 and 4E-BP1 proteins in WT MEFs transiently overexpressing GFP-
DRP1-WT, -S616D, -S637A and double S616D/S637A, treated with vehicle or Ink1341 (200 nM) 
for 24 hr. D-tubulin was used as a loading control. 
(C) Representative confocal images of mitochondrial morphology in WT MEFs transiently 
overexpressing GFP-DRP1-WT, -S616D, -S637A and double S616D/S637A, treated with vehicle 
or Ink1341 (200 nM) for 24 hr. Mitochondria were labeled using an anti-TOM20 antibody. Scale 
bars represent 20 Pm. * and ** indicate GFP-positive transfected cells with elongated and 
fragmented mitochondria, respectively.  
(D) Quantification of mitochondrial morphology in (C). n = 144 for GFP-DRP1-WT + vehicle, n = 
134 for GFP-DRP1-WT + Ink1341, n = 152 for GFP-DRP1-S616D + vehicle, n = 111 for GFP-
DRP1-S616D + Ink1341, n = 166 for GFP-DRP1-S637A + vehicle, n = 153 for GFP-DRP1-637A 
+ Ink1341, n = 162 for GFP-DRP1-S616D/S637A + vehicle, n = 171 for GFP-DRP1-S616D/S637A 
+ Ink1341 from three independent experiments. Data represent mean ± SD. *P <0.05, **P < 0.01, 
***P < 0.001; Student’s t test.  
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Figure S7, related to Figure 7.
Figure S7, related to Figure 7. MTFP1 mediates mTORC1-dependent regulation of 
mitochondrial dynamics and cell survival 
(A) Quantification of levels of the indicated proteins in Figure 7A. Signal intensities were quantified 
by densitometry and normalized with a DRP1 or D-tubulin level. n = 4 per group. Data represent 
mean ± SEM. *P <0.05, **P <0.01; two-way ANOVA with Tukey’s post-hoc test. 
(B) Levels of the indicated proteins in empty vector (control) and MTFP1-overexpressing (MTFP1) 
raptor WT or KO MEFs. α-tubulin was used as a loading control. 
(C) Representative confocal images of mitochondrial morphology in control and MTFP1-
overexpressing raptor WT or KO MEFs. Mitochondria were labeled using an anti-TOM20 antibody. 
Scale bars represent 20 Pm. * and ** indicate cells with elongated and fragmented mitochondria, 
respectively. 
(D) Quantification of mitochondrial morphology in (C). n = 220 for raptor WT + control, n = 263 for 
raptor WT + MTFP1, n = 153 for raptor KO + control, n = 227 for raptor KO + MTFP1 from two 
independent experiments. Data represent mean ± SD. *P <0.05, **P < 0.01; Student’s t test. 
(E) Levels of the indicated proteins in TSC2 WT and KO MEFs silenced with siRNA Control 
(siControl) or siRNA MTFP1 (siMTFP1). D-tubulin was used as a loading control. 
(F) Representative confocal images of mitochondrial morphology in TSC2 WT and KO MEFs 
silenced with siControl or siMTFP1. Mitochondria were labeled using an anti-TOM20 antibody. 
Scale bars represent 20 Pm. * and ** indicate cells with elongated and fragmented mitochondria, 
respectively. 
(G) Quantification of mitochondrial morphology in (F). n = 218 for TSC2 WT + siControl, n = 226 
for TSC2 WT + siMTFP1, n = 270 for TSC2 KO + siControl, n = 297 for TSC2 KO + siMTFP1 from 
three independent experiments. Data represent mean ± SD. **P < 0.01, ***P < 0.001; Student’s t 
test. 
(H) Levels of the indicated proteins in control and MTFP1-overexpressing WT MEFs treated with 
vehicle or Ink1341 (200 nM) for 24 hr. E-actin was used as a loading control. 
 
 
 
 
  
Table S1, related to Q
uantification and Statistical Analysis.
Figure
Param
eter
N
C
om
parison
Statistical tests and significance
Figure 1C
M
itochondrial length
Vehicle(1544), Ink1341(987)
Vehicle vs Ink1341
Student's t-test p=1.65E-73
Figure 1D
Branched m
itochondria
Vehicle(30), Ink1341(30)
Vehicle vs Ink1341
Student's t-test p=1.18E-10
Figure 1E
M
itochondrial num
ber
Vehicle(30), Ink1341(30)
Vehicle vs Ink1341
Student's t-test p=0.0138
Figure 1F
M
itochondrial area
Vehicle(30), Ink1341(30)
Vehicle vs Ink1341
Student's t-test p=0.00441
Figure 1G
Autophagosom
e area
Vehicle(30), Ink1341(30)
Vehicle vs Ink1341
Student's t-test p=4.14E-05
Figure 2B
%
 of cells w
ith the indicated m
itochondria
Vehicle(303), Ink1341(261)
Vehicle vs Ink1341
Student's t-test; Interm
ediate (p<0.001), Fragm
ented (p=0.290), Elongated (p<0.001)
Figure 3C
%
 of cells w
ith the indicated m
itochondria
R
aptor W
T(322), KO
(290)
R
aptor W
T vs KO
Student's t-test; Interm
ediate (p=0.006), Fragm
ented (p=0.517), Elongated (p=0.002)
R
ictor W
T(347), KO
(266)
R
ictor W
T vs KO
Student's t-test; Interm
ediate (p=0.644), Fragm
ented (p=0.803), Elongated (p=0.624)
Figure 4C
%
 of cells w
ith the indicated m
itochondria
TSC
2 W
T(191), KO
(226)
TSC
2 W
T vs KO
Student's t-test; Interm
ediate (p=0.015), Fragm
ented (p=0.002), Elongated (p=0.002)
Figure 5C
M
itochondrial length, F=52.893, p<0.001
4E-BP W
T+Vehicle(810), W
T+Ink1341(504)
W
T+Veh vs W
T+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p<0.001
4E-BPD
KO
+Vehicle(691), D
KO
+Ink1341(719)D
KO
+Veh vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p<0.001
W
T+Veh vs D
KO
+Veh
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.999
W
T+Ink vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p<0.001
Figure 5D
Branched m
itochondria, F=29.996, p<0.0014E-BP W
T+Vehicle(30), W
T+Ink1341(30)
W
T+Veh vs W
T+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p<0.001
4E-BP D
KO
+Vehicle(30), D
KO
+Ink1341(30)
D
KO
+Veh vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.904
W
T+Veh vs D
KO
+Veh
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.999
W
T+Ink vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p<0.001
Figure 5E
M
itochondrial area, F=5.746, p=0.019
4E-BP W
T+Vehicle(30), W
T+Ink1341(30)
W
T+Veh vs W
T+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.034
4E-BP D
KO
+Vehicle(30), D
KO
+Ink1341(30)
D
KO
+Veh vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.851
W
T+Veh vs D
KO
+Veh
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=1.000
W
T+Ink vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.005
Figure 5F
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4E-BP W
T+Vehicle(30), W
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T+Veh vs W
T+Ink
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O
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4E-BP D
KO
+Vehicle(30), D
KO
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D
KO
+Veh vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.006
W
T+Veh vs D
KO
+Veh
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.495
W
T+Ink vs D
KO
+Ink
Tw
o-w
ay AN
O
VA w
ith Tukey's post-hoc p=0.601
Figure 5G
%
 of cells w
ith the indicated m
itochondria
4E-BP W
T+Veh(333), W
T+Ink1341(261)
W
T+Veh vs W
T+Ink
Student's t-test; Interm
ediate (p<0.001), Fragm
ented (p=0.290), Elongated (p<0.001)
4E-BP D
KO
+Veh(315), D
KO
+Ink1341(333)
D
KO
+Veh vs D
KO
+Ink
Student's t-test; Interm
ediate (p=0.331), Fragm
ented (p=0.393), Elongated (p=0.867)
Figure 7C
%
 of cells w
ith the indicated m
itochondria
C
ont+Veh(179), C
ont+Ink1341(115)
C
ont+Veh vs C
ont+Ink1341
Student's t-test; Interm
ediate (p<0.001), Fragm
ented (p=0.156), Elongated (p<0.001)
M
TFP1+Veh(213), M
TFP1+Ink1341(173)
M
TFP1+Veh vs M
TFP1+Ink1341
Student's t-test; Interm
ediate (p=0.051), Fragm
ented (p=0.663), Elongated (p=0.006)
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VA w
ith Tukey's post-hoc p=0.017
C
ont+Ink128 vs M
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ay AN
O
VA w
ith Tukey's post-hoc p=0.022
Figure 7F
C
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Figure S1C
M
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Vehicle(810), R
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ycin(506)
Vehicle vs R
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ycin
Student's t-test p=2.62E-13
Branched m
itochondria
Vehicle(30), R
apam
ycin(30)
Vehicle vs R
apam
ycin
Student's t-test p=0.628
M
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ber
Vehicle(30), R
apam
ycin(30)
Vehicle vs R
apam
ycin
Student's t-test p=0.016
Autophagosom
e area
Vehicle(30), R
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ycin(30)
Vehicle vs R
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ycin
Student's t-test p=0.00147
Figure S2C
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0 hr(4), 3 hr(4), 6 hr(4), 12 hr(4), 24 hr(4)
0 hr vs others
O
ne-w
ay AN
O
VA w
ith D
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D
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Table S1, related to Quantification and Statistical Analysis. Summary of statistical analysis 
 
Movie S1, related to Figure 1. 3-D Volren of mitochondria of wild-type MEFs treated with 
Ink1341 
FIB-SEM 3-D visualization from 30 consecutive serial sections of wild-type MEFs treated with 
Ink1341 (200 nM) for 24 hr. 
 
Movie S2, related to Figure 1. 3-D Volren of mitochondria of wild-type MEFs treated with 
vehicle 
FIB-SEM 3-D visualization from 30 consecutive serial sections of wild-type MEFs treated with 
vehicle for 24 hr. 
 
 
